嵌合抗原受体T细胞在B细胞性血液肿瘤中的研究进展

嵌合抗原受体（CAR）转染的T细胞通过释放细胞因子及细胞毒性T淋巴细胞（CTL）效应可高效杀伤靶抗原阳性的肿瘤细胞,且不受相容性复合体（MHC）的限制.近年欧美多个癌症中心的临床试验表明,CD19靶向的CAR-T细胞输注不仅可使复发状态的B细胞急性淋巴细胞白血病（B-ALL）患者达完全缓解,且分子水平的微小残留病（MRD）也可转阴.其在慢性淋巴细胞白血病、B细胞性恶性淋巴瘤患者中也取得了显著疗效,相信不久的将来该技术必将成为肿瘤综合治疗的重要手段.

Research progress of chimeric antigen receptor-transduced-T cells in B-cell malignancies

Chimeric antigen receptor-transduced-T （CAR-T） cells shows strong cytotoxicity to the tumor with specific antigen by CTL effects and cytokines releasing without MHC-restriction.As multiple clinical trials from cancer centers around the West countries reported recent years,anti-CD19-CAR T cells can not only induce complete remission of B-cell malignancies resistant,but also eliminate the minimal residual disease （MRD） at the molecular level.It is believed that the obstacles from bench to clinic will be cleared and CAR will become one of the main cancer therapies with breakthroughs in comprehensive treatment of tumors.